RT Journal Article
SR Electronic
T1 Effect of exercise therapy on sarcopenia in pancreatic cancer: a study protocol for a randomised controlled trial
JF BMJ Open Gastroenterology
FD BMJ Publishing Group Ltd
SP e000194
DO 10.1136/bmjgast-2017-000194
VO 5
IS 1
A1 Kazunori Yoh
A1 Hiroki Nishikawa
A1 Hirayuki Enomoto
A1 Noriko Ishii
A1 Yoshinori Iwata
A1 Akio Ishii
A1 Yukihisa Yuri
A1 Yuho Miyamoto
A1 Kunihiro Hasegawa
A1 Chikage Nakano
A1 Ryo Takata
A1 Takashi Nishimura
A1 Nobuhiro Aizawa
A1 Yoshiyuki Sakai
A1 Naoto Ikeda
A1 Tomoyuki Takashima
A1 Hiroko Iijima
A1 Shuhei Nishiguchi
YR 2018
UL http://bmjopengastro.bmj.com//content/5/1/e000194.abstract
AB Introduction and purpose Sarcopenia is defined as a decrease in muscle mass and muscle strength, and it has been demonstrated to be an adverse predictor in numerous types of cancers. Exercise therapy (ET) carries multiple health benefits in several diseases. Despite these clinical benefits, there are limited data available regarding patients with pancreatic cancer (PC) undergoing ET. We aim to prospectively examine the effect of ET on sarcopenia in patients with PC.Methods and analysis All clinical stages of PC can be included. When registering study subjects, a precise evaluation of the nutritional status and the daily physical activities performed will be undertaken individually, for each participant. Study participants will be randomly allocated into two groups: (1) the ET and standard therapy group and (2) the standard therapy group. Amelioration of sarcopenia at 3 months postrandomisation will be the primary endpoint. Muscle mass will be calculated using bioimpedance analysis. Sarcopenia will be defined based on the current Asian guidelines. Participants will be instructed to perform exercises with > 3 metabolic equivalents (mets; energy consumption in physical activities/resting metabolic rate) for 60 min/day and to perform exercises with > 23 mets/week. In the ET group, physical activities equal to or greater than walking for 60 min/day will be strongly recommended.Ethics and dissemination The Institutional Review Board at Hyogo College of Medicine has approved this study protocol (approval no. 2772). The final data will be publicly announced. A report releasing the study results will be submitted for publication.Trial registration number UMIN000029271; Pre-results.